Michael J Kraut
Overview
Explore the profile of Michael J Kraut including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kernstine K, Moon J, Kraut M, Pisters K, Sonett J, Rusch V, et al.
Ann Thorac Surg
. 2014 Jul;
98(2):402-10.
PMID: 24980603
Background: Although preoperative chemotherapy (cisplatin-etoposide) and radiotherapy, followed by surgical resection, is considered a standard of care for superior sulcus cancers, treatment is rigorous and relapse limits long-term survival. The...
2.
Edelman M, Harb W, Pal S, Boccia R, Kraut M, Bonomi P, et al.
J Thorac Oncol
. 2012 Sep;
7(10):1618-21.
PMID: 22982661
Background: EC145 is a novel folate-receptor targeted agent consisting of a folate molecule linked to a vinca alkaloid. EC20 is a technetium-labeled folate that assesses the presence of folate receptors...
3.
Schneider B, Kalemkerian G, Ramnath N, Kraut M, Wozniak A, Worden F, et al.
Clin Lung Cancer
. 2010 Jul;
11(4):223-7.
PMID: 20630823
Background: The prognosis for patients with extensive-stage small-cell lung cancer remains poor. This trial was designed to evaluate irinotecan/cisplatin plus maintenance imatinib in patients with c-Kit-positive disease (the transmembrane receptor...
4.
Schneider B, Worden F, Gadgeel S, Parchment R, Hodges C, Zwiebel J, et al.
Invest New Drugs
. 2009 Feb;
27(6):571-8.
PMID: 19225720
Background: Alterations in retinoid signaling appear to be involved in the pathogenesis of small cell lung cancer (SCLC). Fenretinide [N-(4-hydroxyphenyl)retinamide], a synthetic retinoid, inhibits the growth of SCLC cells in...
5.
Schneider B, Kalemkerian G, Kraut M, Wozniak A, Worden F, Smith D, et al.
J Thorac Oncol
. 2008 Dec;
3(12):1454-9.
PMID: 19057272
Introduction: To evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in patients with advanced non-small cell lung cancer after failure of platinum-based therapy. Methods: Patients with...
6.
Gadgeel S, Wozniak A, Ruckdeschel J, Heilbrun L, Venkatramanamoorthy R, Chaplen R, et al.
J Thorac Oncol
. 2008 Nov;
3(11):1293-300.
PMID: 18978565
Introduction: The utility of two-drug chemotherapy regimens in elderly or performance status (PS 2) patients with advanced non-small cell lung cancer (NSCLC) remains to be established. Preclinical studies suggested that...
7.
Fontanesi J, Mott M, Kraut M, Lucas D, Miller P
Sarcoma
. 2008 Jun;
9(3-4):141-5.
PMID: 18521422
Purpose: This is the initial report on the utilization of combined photon irradiation followed by a neutron boost irradiation for the initial management of patients with high-grade non-metastatic soft tissue...
8.
Fontanesi J, Mott M, Kraut M, Lucas D, Miller P
Sarcoma
. 2008 Jun;
8(2-3):83-6.
PMID: 18521399
Background: To define the efficacy of postoperative irradiation in patients with recurrent extra-abdominal desmoid tumors in whom surgical intervention has resulted in microscopically or grossly positive surgical margins. Methods: A...
9.
Fontanesi J, Mott M, Lucas D, Miller P, Kraut M
Sarcoma
. 2008 Jun;
8(2-3):57-61.
PMID: 18521396
Background: Patients who have had initial curative intent therapy for non-metastatic soft tissue sarcoma, and who subsequently relapse at the initial site without evidence of metastatic disease, have various options...
10.
Kalmadi S, Rankin C, Kraut M, Jacobs A, Petrylak D, Adelstein D, et al.
Lung Cancer
. 2007 Nov;
60(2):259-63.
PMID: 18006112
Purpose: The purpose of this open-label phase II SWOG study was to evaluate the activity of gemcitabine (Gemzar; Eli Lilly, Indiana, USA) and cisplatin combination therapy, in patients with unresectable...